Totiomics decodes methylation patterns in circulating cell-free DNA to identify patients most likely to benefit from immune checkpoint therapy — before treatment begins.
How It Works
Three steps. One tube of blood. Actionable methylome-derived predictions that inform treatment decisions across oncology.
A standard 10 mL blood draw provides circulating cell-free DNA. No tissue biopsy required — minimally invasive and suitable for serial monitoring throughout the treatment journey.
Our proprietary cfDNA methylation sequencing pipeline interrogates LINE-1 elements, CpG islands, and immune-regulatory loci — capturing the epigenomic landscape invisible to standard mutation-based tests.
Our machine learning models — trained on multi-centre phase II clinical trial data — integrate methylation scores with immune profiling features to generate a patient-level response probability.
Who We Serve
Whether you're accelerating a drug programme, investigating tumour immunity, or navigating a treatment decision — Totiomics gives you the epigenomic signal you need.
Enrich your immunotherapy trials with predictive biomarker stratification. Reduce cohort sizes, cut development costs, and increase regulatory confidence with validated cfDNA methylation endpoints.
Accelerate discovery with access to our validated methylation analysis pipeline. Integrate cfDNA methylomics into immunology, oncology, or computational biology research programmes.
Before starting immunotherapy, understand your likelihood of response. The Totiomics report gives you and your oncologist a personalised, blood-based prediction to support shared decision-making.
The Platform
Totiomics combines long-read sequencing, genome-wide methylation profiling, and validated machine learning to deliver actionable predictions — not just biomarker correlations.
Combines cfDNA methylation with RNA-seq immune profiling and clinical variables for robust, multi-dimensional predictions.
From sample receipt to clinical report in under 7 days. Designed for real-world clinical workflows, not just research settings.
Models trained and tested on prospective phase II clinical trial data across multiple cancer indications and treatment contexts.
Seamless integration with clinical and research data ecosystems via a secure REST API and HL7/FHIR-compatible reporting.
The Science
Genomic hypomethylation in late-replicating domains and LINE-1 elements is mechanistically coupled to tumour immune evasion. When tumours silence antigen-presentation genes via promoter hypermethylation, they become invisible to T-cells. Totiomics reads these epigenomic signals from a simple blood draw — earlier and more comprehensively than tissue biopsy.
Get Started
Whether you're evaluating Totiomics for a clinical trial, integrating it into your research pipeline, or seeking a test for a patient — our team will guide you through the process.
Research
Peer-reviewed research, conference abstracts, and theses underpinning the Totiomics platform — from epigenetic biomarker discovery to multi-omics immunotherapy prediction.
